Typicality: | 0.396 |
Saliency: | 0.343 |
toward u.s. legislation | 17 | transitive-object |
sale → be affected by → regulatory, clinical and guideline developments | 32 |
negative | neutral | positive |
0.333 | 0.641 | 0.025 |
Raw frequency | 32 |
Normalized frequency | 0.343 |
Modifier score | 0.500 |
Perplexity | 72.991 |